Emergent BioSolutions Inc.

The company is a life sciences enterprise that develops and supplies medical solutions to address public health threats, including chemical, biological, and nuclear hazards, infectious diseases, and emergency health crises. Its operations comprise three primary segments: Commercial Products, Medical Countermeasures, and Services. The Commercial segment supplies opioid overdose treatments, notably NARCAN and KLOXXADO nasal sprays. The Medical Countermeasures segment provides vaccines and therapeutics against severe threats such as smallpox, anthrax, and botulism, featuring ACAM2000, BioThrax, and BAT. The Services segment delivers contract development and manufacturing capabilities for external clients. Its customers include the United States government, foreign governments, healthcare departments, law enforcement agencies, community organizations, pharmacies, and commercial biopharmaceutical companies.

The company operates four development and manufacturing facilities across the United States and Canada, located in Gaithersburg, Canton, Lansing, and Winnipeg. It delivers products globally, supplying medical countermeasures to international partners and distributing its botulism antitoxin to nineteen foreign countries. The provided text does not state the location of its headquarters.

Summary of the business section of Emergent BioSolutions's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 900 employees globally.”